Publications

Showing 9 of 0 results

• Contemporary Clinical Trials Communications

  February 2025

  Real-world enrollment for a prospective clinico-genomic database using a pragmatic technology-enabled platform

  Exarchos A, Bourla A, Kaur M, et al.

  • Clinical research
  • Publication summary
  • Publications

• ESMO Real-World Data and Digital Oncology

  February 2025

  Utility of automated data transfer for cancer clinical trials and considerations for implementation

  Pfeffer M, Deneris M, Shelley A, Salcuni P, Altomare I

  • Clinical research
  • Publication summary
  • Publications
  • EHR-to-EDC

• AI in Precision Oncology

  February 2025

  Using large language models to extract PD-L1 biomarker data from electronic health records

  Cohen A, Adamson B, Larch J, Amster G;

  • Publication summary
  • Publications
  • Machine learning

• ASCO GU

  February 2025

  Real-world treatment patterns in patients diagnosed with metastatic castration-resistant prostate cancer in the US, 2018-2023

  Efstathiou E, Li W, Roose J, et al.

  • Publication summary
  • Publications
  • Prostate cancer

• ASCO GU

  February 2025

  Real-world safety of first-line therapies for locally advanced or metastatic urothelial cancer in the US

  Nizam A, Kearney M, Mahmoudpour S, et al.

  • Publication summary
  • Publications
  • Urothelial cell carcinoma

• ASCO GU

  February 2025

  Retrospective, observational analysis of real-world safety outcomes in sacituzumab govitecan-treated patients with locally advanced/metastatic urothelial cancer

  Parikh M, McMahon P, Eng S, et al.

  • Publication summary
  • Publications
  • Urothelial cell carcinoma

• ESMO Real-World Data and Digital Oncology

  February 2025

  Characterisation of oncology EHR-derived real-world data in the UK, Germany, and Japan

  Adamson B, Horne E, Xu C, et al.

  • Real-world evidence
  • Publication summary
  • Publications
  • Data science
  • Methodology
  • HTA and market access

• Oncology and Therapy

  January 2025

  Niraparib as first-line maintenance therapy in patients with stage III ovarian cancer and no visible residual disease: AR1ZE real-world study

  Chase D, Hanna M, Lim J, et al.

  • Publication summary
  • Publications
  • Ovarian cancer

• ESMO Open

  January 2025

  Comparative overall survival of CDK4/6 inhibitors plus an aromatase inhibitor in HR+/HER2− metastatic breast cancer in the US real-world setting

  Rugo H.S., Layman R.M., Lynce F, et al.

  • Real-world evidence
  • Publication summary
  • Publications
  • Comparative effectiveness
  • Metastatic breast cancer